DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for elderly lymphoma patients: drug combo shows promise in early trial
Disease control Recruiting nowThis study tests a new combination of three drugs (chidamide, rituximab, and polatuzumab vedotin) in elderly patients with a specific type of lymphoma called double-positive DLBCL. The goal is to see how well the treatment shrinks tumors and controls the disease. About 58 people …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New combo therapy targets tough-to-treat lymphoma
Disease control Recruiting nowThis study tests a drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a fast-growing lymphoma (DLBCL) that has high-risk features. About 50 participants will receive the combination to see if it improves remission rates. The goal is to fi…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
New hope for aggressive brain cancer: 3-drug combo targets relapsed lymphoma
Disease control Recruiting nowThis study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or stopped responding to treatment. The goal is to see if this drug cocktail can shrink tumors and improve surv…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New hope for lymphoma: experimental drug combo takes on standard care in major trial
Disease control Recruiting nowThis study compares an experimental drug (odronextamab) plus chemotherapy against the current standard treatment (rituximab plus chemotherapy) for people with untreated diffuse large B-cell lymphoma. About 904 participants will be enrolled to see if the new combination works bett…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
New Dual-Targeting CAR t therapy aims to outperform standard treatment for blood cancer
Disease control Recruiting nowThis Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 03:08 UTC
-
New CAR-T therapy aims to control Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new treatment called Talikabtagene autoleucel (NexCAR19) for adults with certain blood cancers that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated May 26, 2026 03:07 UTC
-
New hope for older lymphoma patients: antibody clears hidden cancer DNA
Disease control Recruiting nowThis study is for people aged 70 and older with a type of blood cancer called diffuse large B-cell lymphoma. After initial chemotherapy, some patients still have tiny traces of cancer DNA in their blood, which raises the risk of the cancer coming back. Researchers are testing whe…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Danielle Wallace • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New hope for hard-to-treat brain lymphoma: cell therapy trial launches
Disease control Recruiting nowThis study tests a new treatment called Anbal-cabtagene autoleucel (Anbal-cel) for people with a type of lymphoma that affects the brain or spinal cord and has not responded to standard therapy or has returned. The treatment uses a patient's own immune cells, which are collected,…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
Last-Resort cancer drug made available through expanded access program
Disease control AVAILABLEThis program offers the investigational drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of approved treatments and cannot join a clinical trial. It is not a cure but aims to control the disease. Patients must get approval from …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New study follows CAR-T cells in blood cancer patients
Disease control Recruiting nowThis study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track the CAR-T cells in the body after infusion and measure how the disease responds. The study includes 45 patients who have not improved aft…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New hope for lymphoma patients with hepatitis b: maintenance drug aims to prevent relapse
Disease control Recruiting nowThis study tests whether the drug chidamide can help keep diffuse large B-cell lymphoma (DLBCL) from coming back in patients who also have hepatitis B. Participants must have achieved complete remission after initial chemotherapy (R-CHOP). The trial will compare progression-free …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE3 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated May 26, 2026 03:03 UTC
-
New hope for aggressive blood cancer: experimental drug rocbrutinib faces off against standard care
Disease control Recruiting nowThis study tests a new drug called rocbrutinib in adults with a type of aggressive lymphoma (non-GCB DLBCL) that has come back or not responded to treatment. About 150 participants will receive either rocbrutinib alone or one of two standard chemotherapy combinations. The main go…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
Last-Resort CAR-T therapy opens to patients outside clinical trials
Disease control AVAILABLEThis program provides access to tisagenlecleucel (CTL019), a CAR-T cell therapy, for people with serious blood cancers like lymphoma or leukemia who have no other treatment options and cannot join a clinical trial. Doctors must request the therapy for individual patients, and the…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Smart scans and DNA tests guide lymphoma therapy in new trial
Disease control Recruiting nowThis study tests a personalized approach for people with untreated diffuse large B-cell lymphoma (DLBCL). After initial chemotherapy, doctors use PET scans and blood DNA tests to decide if a patient can safely get less chemotherapy or needs a stronger drug called glofitamab. The …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for elderly lymphoma patients: targeted combo shows promise
Disease control Recruiting nowThis study tests a new drug combination for people aged 70 and older who have a specific type of aggressive lymphoma (DLBCL) that has not been treated before. Participants receive a targeted drug (chidamide) plus a reduced-dose chemotherapy, followed by maintenance therapy with c…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Ou Bai, MD/PHD • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New cancer pill shows promise in early trial for tough tumors
Disease control Recruiting nowThis early-stage study tests an experimental drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The drug works by boosting the immune system to fight tumors. The main goals are to check safety and find the right dose, with a later …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New combo therapy aims to tame lymphoma in seniors
Disease control Recruiting nowThis study is for people aged 65 and older with diffuse large B-cell lymphoma (DLBCL) or similar lymphomas. The goal is to see if adding the drug glofitamab to standard chemotherapy can improve treatment results with fewer side effects. About 42 participants will receive a combin…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma in new trial
Disease control Recruiting nowThis study tests a new treatment called TC011, which uses a patient's own immune cells modified to find and attack cancer cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial aims to find the safest dos…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Gene-Matched therapy aims to outsmart aggressive lymphoma
Disease control Recruiting nowThis study tests a new approach for people newly diagnosed with a fast-growing blood cancer called diffuse large B-cell lymphoma that has a specific genetic change (TP53 mutation). The treatment is matched to each person's genetic subtype to improve effectiveness. About 35 adults…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called NX-2127 in adults with certain blood cancers (like CLL or lymphoma) that have returned or not improved after other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New drug targets Hard-to-Treat blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called NX-5948 in adults with certain blood cancers (like CLL or lymphoma) that have come back or stopped responding to treatment. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to find a safe dose …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New injection shows promise for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage study tests a new drug called KSV01 in 18 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check safety and find the right dose. Researchers will monitor side effects and look for signs that the…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Last-Resort hope: new drug offered to lymphoma patients with no options left
Disease control AVAILABLEThis program gives people with certain types of lymphoma (like follicular lymphoma or diffuse large B-cell lymphoma) who have tried all other treatments access to an experimental drug called odronextamab. The goal is to provide a possible treatment option when no others are avail…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
Lifestyle plan aims to boost Well-Being in lymphoma survivors
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin lymphoma, DLBCL, or PMBCL). Participants must be between 18 and 50 years old and in remission for 3 to 10 years. The study wi…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated May 22, 2026 14:02 UTC
-
Can a herbal capsule beat chemo fatigue in lymphoma survivors?
Symptom relief Recruiting nowThis study tests whether Xinlikang capsules can help reduce severe tiredness and improve immune health in people with diffuse large B-cell lymphoma who have finished chemotherapy and are in remission. About 80 adults will receive either the capsule or a placebo for several weeks.…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2, PHASE3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated May 22, 2026 13:52 UTC
-
Massive blood cancer registry launches to track Real-World treatments
Knowledge-focused Recruiting nowThis study is a registry that will follow about 2950 adults in Germany with certain blood cancers (like CLL, DLBCL, and others). Researchers will collect information on the treatments people receive, how their disease progresses, and their quality of life. No new treatments are g…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated May 26, 2026 03:08 UTC
-
Rare lymphoma transformation under study: when aggressive cancer turns mild
Knowledge-focused Recruiting nowThis study looks at a rare event where an aggressive lymphoma (DLBCL) comes back as a slower-growing type. Researchers will review medical records of 50 adults to understand how often this happens, what treatments work best, and how long people live. The goal is to gather informa…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC